UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant to Rule13a-16 or15d-16
under the Securities Exchange Act of 1934
Commission File Number001-37518
Benitec Biopharma Limited
(Translation of registrant’s name into English)
Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b): n/a
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Benitec Biopharma Limited | ||||||
| Date: May 1, 2018 | By: | /s/ GREG WEST | ||||
| Name: | Greg West | |||||
| Title: | Company Secretary | |||||
This report onForm 6-K is incorporated by reference in the Registration Statement onForm F-3 of Benitec Biopharma Limited(No. 333-218400) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 1, 2017, and shall be deemed to be a part thereof from the date on which this report is furnished to the SEC, to the extent not superseded by documents or reports subsequently filed or furnished. It contains as exhibits the following documents:
EXHIBIT INDEX
Exhibit Number | Description | |
| 99.1 | Subscription Agreement dated as of April 27, 2018 | |